Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC.

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

Administering durvalumab before and after CRT did not provide a benefit over CRT alone in a phase 3 trial of patients with intermediate- and high-risk oropharyngeal cancer.

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

This article was originally published on Stateline. In a clear rebuke of recent federal health policy, 15 Democratic governors announced Wednesday they’ve formed a public health alliance that breaks ...

For patients with advanced or metastatic RCC, fruquintinib plus sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus.

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.

In TNBC, pembrolizumab at a tenth of the current standard dose, plus chemotherapy, increased pCR compared to chemotherapy alone.

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

Prior authorization is placing a growing burden on radiation oncologists, leading to treatment delays and suboptimal treatment, and compromising patient safety, according to a survey presented at the ...